Targeting and Deploying Optimum Radiopharmaceuticals to Treat Cancer with Jack Hoppin and John Babich Ratio Therapeutics TRANSCRIPT
Download PDFSep 27, 2022
Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells...
Sep 27, 2022
Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells...
Targeting the Adenosine Pathway to Stimulate the Immune System to Destroy Tumors with Dr. Robert Ross Surface Oncology TRANSCRIPT
Download PDFSep 22, 2022
Dr. Robert Ross is the CEO of Surface Oncology, which is focused on immune modulation in the treatment of cancers. Their hypothesis is that IL-27, a cytokine, is telling the immune system to ignore the cancer and providing a hiding place for the cancer cells. By administering their drug SRF 388 to bind up all the IL-27,...
Sep 22, 2022
Dr. Robert Ross is the CEO of Surface Oncology, which is focused on immune modulation in the treatment of cancers. Their hypothesis is that IL-27, a cytokine, is telling the immune system to ignore the cancer and providing a hiding place for the cancer cells. By administering their drug SRF 388 to bind up all the IL-27,...
Administering Cellular Therapy for Solid Tumors and Blood Cancers Without Lymphodepleting Chemotherapy with Greg Frost EXUMA Biotech TRANSCRIPT
Download PDFSep 21, 2022
Greg Frost is the Chairman and CEO of EXUMA Biotech, which is working on a cancer cellular therapy that can be administered in a patient without lymphodepletion from chemotherapy. Traditionally, it was thought that some cells needed to be eliminated before new cells could be introduced. EXUMA is working on a rapid point...